Overview
- Authors:
-
-
Edward W. Flückiger
-
Pharmaceutical Division, Preclinical Research, Sandoz Ltd., Basle, Switzerland
-
Emilio Pozo
-
Pharmaceutical Division, Experimental Therapeutics, Sandoz Ltd., Basle, Switzerland
-
Klaus Werder
-
Department of Medicine Innenstadt, University of Munich, Munich, Federal Republic of Germany
Access this book
Other ways to access
Table of contents (5 chapters)
-
-
- Edward W. Flückiger, Emilio del Pozo, Klaus von Werder
Pages 1-23
-
- Edward W. Flückiger, Emilio del Pozo, Klaus von Werder
Pages 24-64
-
- Edward W. Flückiger, Emilio del Pozo, Klaus von Werder
Pages 65-101
-
- Edward W. Flückiger, Emilio del Pozo, Klaus von Werder
Pages 102-152
-
- Edward W. Flückiger, Emilio del Pozo, Klaus von Werder
Pages 153-218
-
Back Matter
Pages 219-226
About this book
Lactogenic hormone activity was first observed in bovine pituitary extracts by Stricker and Griiter in 1928, working in Bouin's laboratory in Strasbourg. Since that time prolactin has been shown to exist in anterior pituitary extracts of almost all vertebrate species investigated. Although its biology was extensively studied in many mammalian species, the existence of prolactin in the human was generally doubted, despite the positive evidence produced by such researchers as Pasteels. This can partly be explained by the fact that human growth hormone isolated in 1961, is itself a potent lactogen, in contrast to nonprimate growth hormones, and is present in the normal human pituitary in much greater amounts than prolactin. As a result there was a lag of nearly 10 years until prolactin was unanimously accepted as a hormone of the human pituitary, separate from human growth hormone. In 1970 new bioassay techniques permitted the demonstration of prolactin bioactivity in the serum of postpartum women and galactorrhea patients, and chromatographic methods led to the isolation and purification of human prolactin allowing the establishment of a specific radioimmunoassay for this hormone. This opened the road to the understanding of prolactin physiology and pathophysiology in the human, which has revolutionized clinical neuroendocrinology and reproductive endocrinology. Particularly hyperprolactinemia has turned out to be one of the most common endocrine syndromes.
Authors and Affiliations
-
Pharmaceutical Division, Preclinical Research, Sandoz Ltd., Basle, Switzerland
Edward W. Flückiger
-
Pharmaceutical Division, Experimental Therapeutics, Sandoz Ltd., Basle, Switzerland
Emilio Pozo
-
Department of Medicine Innenstadt, University of Munich, Munich, Federal Republic of Germany
Klaus Werder
